Single-agent carboplatinum for advanced seminoma a phase II study

✍ Scribed by Hans-Joachim Schmoll; Andreas Harstrick; Carsten Bokemeyer; Klaus-Peter Dieckmann; Christoph Clemm; Wolfgang E. Berdel; Rainer Souchon; Christoph Schöber; Hansjochen Wilke; Hubert Poliwoda

• Book ID: 102672028
• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 672 KB
• Volume: 72
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19930701)72:1<237::aid-cncr2820720142>3.0.co;2-l

✦ Synopsis

Background. To reduce the side effects of cisplatinbased combination chemotherapy, the activity of carboplatinum was evaluated in patients with advanced seminoma.

Methods. Forty-two evaluable patients with advanced seminoma (defined as abdominal lymph nodes > 5 cm or supradiaphragmatic or visceral disease) received single-agent carboplatinum at a dose of 400 mg/m2 intravenously every 4 weeks for a maximum of six cycles. The median follow-up was 31 months (18-67 months).

Thirty patients (71%) achieved a complete remission (CR 21 chemotherapy alone, 9 with additional surgery), 8 patients (19%) a partial remission (PR), and 4 patients had disease progression (10%). Patients with metastases confined to the lymph nodes had a significantly higher remission rate than patients with visceral metastases (97% versus 50%; P < 0.002). Elevation of lactate Results.